CPHI Quote, Financials, Valuation and Earnings

Oragenics, Inc. has a net margin of -86.16% compared to China Pharma Holdings, Inc.'s net margin of --. China Pharma Holdings, Inc.'s return on equity of -43.41% beat Oragenics, Inc.'s return on equity of -509.23%.

China Pharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 139.49%. Given that Oragenics, Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe Oragenics, Inc. is more attractive than China Pharma Holdings, Inc..

China Pharma Holdings, Inc. has a beta of 1.028, which suggesting that the stock is 2.826% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.

China Pharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Pharma Holdings, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.

China Pharma Holdings, Inc. quarterly revenues are $756.2K, which are larger than Oragenics, Inc. quarterly revenues of --. China Pharma Holdings, Inc.'s net income of -$651.5K is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, China Pharma Holdings, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Pharma Holdings, Inc. is 1.06x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -86.16% compared to China Pharma Holdings, Inc.'s net margin of --. China Pharma Holdings, Inc.'s return on equity of -43.41% beat Palatin Technologies's return on equity of --.

China Pharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than China Pharma Holdings, Inc., analysts believe Palatin Technologies is more attractive than China Pharma Holdings, Inc..

China Pharma Holdings, Inc. has a beta of 1.028, which suggesting that the stock is 2.826% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

China Pharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Pharma Holdings, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

China Pharma Holdings, Inc. quarterly revenues are $756.2K, which are larger than Palatin Technologies quarterly revenues of --. China Pharma Holdings, Inc.'s net income of -$651.5K is higher than Palatin Technologies's net income of --. Notably, China Pharma Holdings, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Pharma Holdings, Inc. is 1.06x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -86.16% compared to China Pharma Holdings, Inc.'s net margin of --. China Pharma Holdings, Inc.'s return on equity of -43.41% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

China Pharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3349.98%. Given that Theriva Biologics, Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe Theriva Biologics, Inc. is more attractive than China Pharma Holdings, Inc..

China Pharma Holdings, Inc. has a beta of 1.028, which suggesting that the stock is 2.826% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

China Pharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Pharma Holdings, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

China Pharma Holdings, Inc. quarterly revenues are $756.2K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. China Pharma Holdings, Inc.'s net income of -$651.5K is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, China Pharma Holdings, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Pharma Holdings, Inc. is 1.06x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Yubo International Biotech Ltd. has a net margin of -86.16% compared to China Pharma Holdings, Inc.'s net margin of -11740.4%. China Pharma Holdings, Inc.'s return on equity of -43.41% beat Yubo International Biotech Ltd.'s return on equity of --.

China Pharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Yubo International Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that China Pharma Holdings, Inc. has higher upside potential than Yubo International Biotech Ltd., analysts believe China Pharma Holdings, Inc. is more attractive than Yubo International Biotech Ltd..

China Pharma Holdings, Inc. has a beta of 1.028, which suggesting that the stock is 2.826% more volatile than S&P 500. In comparison Yubo International Biotech Ltd. has a beta of 0.750, suggesting its less volatile than the S&P 500 by 25.002%.

China Pharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Yubo International Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. China Pharma Holdings, Inc. pays -- of its earnings as a dividend. Yubo International Biotech Ltd. pays out -- of its earnings as a dividend.

China Pharma Holdings, Inc. quarterly revenues are $756.2K, which are larger than Yubo International Biotech Ltd. quarterly revenues of --. China Pharma Holdings, Inc.'s net income of -$651.5K is lower than Yubo International Biotech Ltd.'s net income of -$310.2K. Notably, China Pharma Holdings, Inc.'s price-to-earnings ratio is -- while Yubo International Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for China Pharma Holdings, Inc. is 1.06x versus 12.99x for Yubo International Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.